Lista de obras -

A Live Human Parainfluenza Type 3 Virus Vaccine Is Attenuated and Immunogenic in Healthy Infants and Children ⬇️

artículo científico publicado el 1 de diciembre de 1995

A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants

artículo científico publicado en 2003

Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response

artículo científico publicado en 2010

Analysis of Variola and Vaccinia Virus Neutralization Assays for Smallpox Vaccines ⬇️

artículo científico publicado el 16 de mayo de 2012

Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of Dryvax

artículo científico publicado en 2007

Antibody responses to vaccinia membrane proteins after smallpox vaccination

artículo científico publicado en 2007

Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induced by IIIB and MN recombinant gp120 vaccines. The NIAID AIDS Vaccine Evaluation Group.

artículo científico publicado en 1996

CD4+ T cells provide intermolecular help to generate robust antibody responses in vaccinia virus-vaccinated humans

artículo científico publicado en 2013

Characterization of a live, attenuated human parainfluenza type 3 virus candidate vaccine strain.

artículo científico publicado en 1995

Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge

artículo científico publicado en 2007

Clinical responses to undiluted and diluted smallpox vaccine

artículo científico publicado en 2002

Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults

artículo científico publicado en 2007

Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax in healthy vaccinia-naive adults

artículo científico publicado en 2008

Detection of binding antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins following recombinant gp160 immunization measured by flow cytometry and enzyme immunoassays. The AIDS Vaccine Clinical Trials Networ

artículo científico publicado en 1992

Dose-dependent neutralizing-antibody responses to vaccinia

artículo científico publicado en 2004

Dose-related effects of smallpox vaccine

artículo científico publicado en 2002

Evaluation of a cold-adapted influenza B/Texas/84 reassortant virus (CRB-87) vaccine in young children ⬇️

artículo científico publicado el 1 de septiembre de 1992

Evaluation of a live attenuated, cold-adapted parainfluenza virus type 3 vaccine in children ⬇️

artículo científico publicado el 1 de agosto de 1992

Evaluation of bovine, cold-adapted human, and wild-type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees.

artículo científico publicado en 1991

Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children

artículo científico publicado en 2004

Evaluation of live attenuated influenza vaccines in children 6-18 months of age: safety, immunogenicity, and efficacy. National Institute of Allergy and Infectious Diseases, Vaccine and Treatment Evaluation Program and the Wyeth-Ayerst ca Influenza

artículo científico publicado en 1996

Evaluation of smallpox vaccines using variola neutralization

artículo científico publicado en 2009

Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses

artículo científico publicado en 1999

Flow-cytometric detection of vaccinia-induced memory effector CD4(+), CD8(+), and gamma delta TCR(+) T cells capable of antigen-specific expansion and effector functions

artículo científico publicado en 2005

HIV-1 recombinant gp160 vaccine induced antibodies in serum and saliva. The NIAID AIDS Vaccine Clinical Trials Network

scientific article published on 01 February 1995

Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants

artículo científico publicado en 2005

Immune status in a primary smallpox vaccinee who failed to develop an immunization site reaction

artículo científico publicado en 2005

Immunity to influenza in older adults with chronic obstructive pulmonary disease

artículo científico publicado en 2004

Immunization of infants and young children with live attenuated trivalent cold-recombinant influenza A H1N1, H3N2, and B vaccine

artículo científico publicado el 1 de abril de 1992

Improved assay to detect neutralizing antibody following vaccination with diluted or undiluted vaccinia (Dryvax) vaccine

artículo científico publicado en 2003

Increased anti-influenza A virus cytotoxic T cell activity following vaccination of the chronically ill elderly with live attenuated or inactivated influenza virus vaccine

artículo científico publicado en 1995

Induction of human T cell-mediated immune responses after primary and secondary smallpox vaccination

artículo científico publicado en 2004

Induction of mucosal antibodies by live attenuated and inactivated influenza virus vaccines in the chronically ill elderly

artículo científico publicado en 1996

Influenza Virus Vaccination of Patients With Chronic Lung Disease ⬇️

artículo científico publicado el 5 de noviembre de 1997

Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children

artículo científico publicado en 2011

Lymphocyte proliferative responses following immunization with human immunodeficiency virus recombinant GP160. The NIAID AIDS Vaccine Clinical Trials Network

artículo científico publicado el 1 de enero de 1992

Multidose, live attenuated, cold-recombinant, trivalent influenza vaccine in infants and young children

scientific article published on 01 May 1994

Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old.

artículo científico publicado en 2004

Prevaccine Determination of the Expression of Costimulatory B7 Molecules in Activated Monocytes Predicts Influenza Vaccine Responses in Young and Older Adults

article

Recombinant gp160 vaccination schedule and MHC HLA type as factors influencing cellular responses to HIV-1 envelope glycoprotein. NIAID AIDS Vaccine Clinical Trials Network

artículo científico publicado en 1995

Reducing the Dose of Smallpox Vaccine Reduces Vaccine‐Associated Morbidity without Reducing Vaccination Success Rates or Immune Responses

article

Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillance

artículo científico publicado en 1989

Response to smallpox vaccine in persons immunized in the distant past

artículo científico publicado en 2003

Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario

artículo científico publicado en 2013

Safety and immunogenicity of varying dosages of trivalent inactivated influenza vaccine administered by needle-free jet injectors

artículo científico publicado en 2001

Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children

artículo científico publicado en 2001

Serum antibody responses after intradermal vaccination against influenza

artículo científico publicado en 2004

Stability of Undiluted and Diluted Vaccinia‐Virus Vaccine, Dryvax ⬇️

artículo científico publicado el 2 de abril de 2003

Temperature-sensitive phenotype of the human parainfluenza virus type 3 candidate vaccine strain (cp45) correlates with a defect in the L gene

artículo científico publicado en 1996

Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers

artículo científico publicado en 2005

Vaccine-induced antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins. NIAID AIDS Vaccine Clinical Trials Network

artículo científico publicado en 1994

Lista de obras de

A Live Human Parainfluenza Type 3 Virus Vaccine Is Attenuated and Immunogenic in Healthy Infants and Children ⬇️

A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants

Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response

Analysis of Variola and Vaccinia Virus Neutralization Assays for Smallpox Vaccines ⬇️

Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of Dryvax

Antibody responses to vaccinia membrane proteins after smallpox vaccination

Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induced by IIIB and MN recombinant gp120 vaccines. The NIAID AIDS Vaccine Evaluation Group.

CD4+ T cells provide intermolecular help to generate robust antibody responses in vaccinia virus-vaccinated humans

Characterization of a live, attenuated human parainfluenza type 3 virus candidate vaccine strain.

Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge

Clinical responses to undiluted and diluted smallpox vaccine

Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults

Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax in healthy vaccinia-naive adults

Detection of binding antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins following recombinant gp160 immunization measured by flow cytometry and enzyme immunoassays. The AIDS Vaccine Clinical Trials Networ

Dose-dependent neutralizing-antibody responses to vaccinia

Dose-related effects of smallpox vaccine

Evaluation of a cold-adapted influenza B/Texas/84 reassortant virus (CRB-87) vaccine in young children ⬇️

Evaluation of a live attenuated, cold-adapted parainfluenza virus type 3 vaccine in children ⬇️

Evaluation of bovine, cold-adapted human, and wild-type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees.

Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children

Evaluation of live attenuated influenza vaccines in children 6-18 months of age: safety, immunogenicity, and efficacy. National Institute of Allergy and Infectious Diseases, Vaccine and Treatment Evaluation Program and the Wyeth-Ayerst ca Influenza

Evaluation of smallpox vaccines using variola neutralization

Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses

Flow-cytometric detection of vaccinia-induced memory effector CD4(+), CD8(+), and gamma delta TCR(+) T cells capable of antigen-specific expansion and effector functions

HIV-1 recombinant gp160 vaccine induced antibodies in serum and saliva. The NIAID AIDS Vaccine Clinical Trials Network

Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants

Immune status in a primary smallpox vaccinee who failed to develop an immunization site reaction

Immunity to influenza in older adults with chronic obstructive pulmonary disease

Immunization of infants and young children with live attenuated trivalent cold-recombinant influenza A H1N1, H3N2, and B vaccine

Improved assay to detect neutralizing antibody following vaccination with diluted or undiluted vaccinia (Dryvax) vaccine

Increased anti-influenza A virus cytotoxic T cell activity following vaccination of the chronically ill elderly with live attenuated or inactivated influenza virus vaccine

Induction of human T cell-mediated immune responses after primary and secondary smallpox vaccination

Induction of mucosal antibodies by live attenuated and inactivated influenza virus vaccines in the chronically ill elderly

Influenza Virus Vaccination of Patients With Chronic Lung Disease ⬇️

Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children

Lymphocyte proliferative responses following immunization with human immunodeficiency virus recombinant GP160. The NIAID AIDS Vaccine Clinical Trials Network

Multidose, live attenuated, cold-recombinant, trivalent influenza vaccine in infants and young children

Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old.

Prevaccine Determination of the Expression of Costimulatory B7 Molecules in Activated Monocytes Predicts Influenza Vaccine Responses in Young and Older Adults

Recombinant gp160 vaccination schedule and MHC HLA type as factors influencing cellular responses to HIV-1 envelope glycoprotein. NIAID AIDS Vaccine Clinical Trials Network

Reducing the Dose of Smallpox Vaccine Reduces Vaccine‐Associated Morbidity without Reducing Vaccination Success Rates or Immune Responses

Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillance

Response to smallpox vaccine in persons immunized in the distant past

Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario

Safety and immunogenicity of varying dosages of trivalent inactivated influenza vaccine administered by needle-free jet injectors

Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children

Serum antibody responses after intradermal vaccination against influenza

Stability of Undiluted and Diluted Vaccinia‐Virus Vaccine, Dryvax ⬇️

Temperature-sensitive phenotype of the human parainfluenza virus type 3 candidate vaccine strain (cp45) correlates with a defect in the L gene

Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers

Vaccine-induced antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins. NIAID AIDS Vaccine Clinical Trials Network